Multidrug-resistant to extensively drug resistant tuberculosis: what is next?

Simple item page
dc.contributor.authorJain, Amitaen_US
dc.contributor.authorDixit, Pratimaen_US
dc.date.accessioned2008-11-12en_US
dc.date.accessioned2009-06-01T14:38:25Z
dc.date.available2008-11-12en_US
dc.date.available2009-06-01T14:38:25Z
dc.date.issued2008-11-12en_US
dc.description76 references.en_US
dc.description.abstractDrug resistant tuberculosis is a man made problem. While tuberculosis is hundred percent curable, multidrug resistant tuberculosis (MDR-TB) is difficult to treat. Inadequate and incomplete treatment and poor treatment adherence has led to a newer form of drug resistance known as extensively drug resistant tuberculosis (XDR-TB). XDR-TB is defined as tuberculosis caused by Mycobacterium tuberculosis strain, which is resistant to at least rifampicin and isoniazid among the first line anti tubercular drugs (MDR-TB) in addition to resistance to any fluroquinolones and at least one of three injectable second line anti tubercular drugs i.e. amikacin, kanamycin and/or capreomycin. Mismanagement of tuberculosis paves the way to drug resistant tuberculosis. Emergence of XDR-TB is reported world wide. Reported prevalence rates of XDR-TB of total MDR cases are; 6.6% overall worldwide, 6.5% in industrialized countries, 13.6% in Russia and Eastern Europe, 1.5% in Asia, 0.6% in Africa and Middle East and 15.4% in Republic of Korea. Better management and control of tuberculosis specially drug resistant TB by experienced and qualified doctors, access to standard microbiology laboratory,co-morbitidy of HIV and tuberculosis,new anti-TB drug regimens, better diagnostic tests,international standards for second line drugs (SLD)-susceptibility testing,invention of newer anti- tubercular molecules and vaccines and knowing the real magnitude of XDR-TB are some of the important issues to be addressed for effective prevention and management of XDR-TB.en_US
dc.description.affiliationPost Graduate Department of Microbiology, CSM Medical University, Lucknow 226 003, India. amita602002@yahoo.comen_US
dc.identifier.citationJain A, Dixit P. Multidrug-resistant to extensively drug resistant tuberculosis: what is next? Journal of Biosciences. 2008 Nov; 33(4): 605-16en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/110970
dc.language.isoengen_US
dc.source.urihttps://www.ias.ac.in/jbiosci/index.htmlen_US
dc.subject.meshAcquired Immunodeficiency Syndrome --complicationsen_US
dc.subject.meshAntibiotics, Antitubercular --pharmacologyen_US
dc.subject.meshDrug Resistance, Multiple, Bacterialen_US
dc.subject.meshHIV Infections --complicationsen_US
dc.subject.meshHumansen_US
dc.subject.meshMicrobial Sensitivity Testsen_US
dc.subject.meshMycobacterium tuberculosis --drug effectsen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshTuberculosis --complicationsen_US
dc.titleMultidrug-resistant to extensively drug resistant tuberculosis: what is next?en_US
dc.typeJournal Articleen_US
dc.typeReviewen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of Biosciences